Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,741.00
Bid: 1,741.00
Ask: 1,741.50
Change: -34.00 (-1.92%)
Spread: 0.50 (0.029%)
Open: 1,770.00
High: 1,770.00
Low: 1,741.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Energy stocks lift UK's FTSE 100, Vodafone shines

Mon, 18th Dec 2023 17:21

Vodafone jumps as Iliad offers to merge Italian units

*

Entain gains on Jefferies upgrade

*

FTSE 100 up 0.5%, FTSE 250 adds 0.1%

Dec 18 (Reuters) - Britain's FTSE 100 climbed on Monday as heavyweight energy stocks rose, tracking strength in crude oil prices, while Vodafone's shares topped the list of gainers after telecom firm Iliad submitted a proposal to create a joint venture in Italy.

The blue-chip FTSE 100 gained 0.5%, while the more domestically focused FTSE 250 mid-cap index edged 0.1% higher.

Vodafone jumped 3.9% after Iliad said it submitted a proposal to the telecom company to merge their Italian businesses.

Heavyweight energy stocks added 1.5%, tracking a jump in crude oil prices, as mounting attacks by the Iran-aligned Yemeni Houthi militant group on ships in the Red Sea disrupted maritime trade.

"Given the importance of the Red Sea and Suez Canal as a crucial transit point for both crude oil and natural gas these suspensions mean that cargos face a lengthy diversion around the Horn of Africa which will add significant costs to company supply chains," said Michael Hewson, chief market analyst at CMC Markets UK.

Looking ahead, data due this week includes domestic and euro zone inflation, along with GDP estimates from Britain and the U.S.

The FTSE 100 is extending three consecutive weeks of gains on the back of hopes that the U.S. Federal Reserve could consider cutting interest rates soon.

Tempering some of those expectations, Atlanta Fed President Raphael Bostic pushed back on Friday saying the U.S. central bank can begin reducing rates "sometime in the third quarter" of 2024 if inflation falls as expected. New York Fed President John Williams has also sought to cool rate-cut forecasts.

Among other individual stocks, GSK gained 1.6% after the drugmaker said its cancer drug combination met its primary goal in a late-stage trial.

Entain advanced 4.1% after Jefferies upgraded the sports betting firm's rating to "buy" from "hold".

On the downside, Fresnillo lost 5.2% after Morgan Stanley downgraded its rating to "underweight" from "equal-weight". (Reporting by Shashwat Chauhan and Shubham Batra in Bengaluru; Editing by Sonia Cheema and Janane Venkatraman)

More News
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.